Linda Jo Bone Jeng, MD, PhD

• Whittier College, BA, Scholars Program/Biochemistry, 1990
• University of Pennsylvania School of Medicine, MD, 1998
• University of Pennsylvania, Cell & Molecular Biology, PhD, 1998
• University Hospitals of Cleveland, Residency, Pediatrics & Medical Genetics, 2004
• Case Western Reserve University, Fellowship, Clinical Molecular Genetics, 2005

Dr. Jeng is trained in cell and molecular biology and is board certified in clinical molecular genetics and clinical genetics by the American Board of Medical Genetics and Genomics. She has extensive experience in molecular genetics and has been a clinical molecular laboratory director since 2005. Her research interests include development of new molecular tests that can be offered in the clinical setting with particular interest in translational research and clinical molecular genetics.

Dr. Jeng played a critical role in the development of the first CLIA validated NGS sequencing panel for Juvenile Myelomonocytic Leukemia (JMML) at the University of California, San Francisco in collaboration with Dr. Mignon Loh.  Dr. Jeng was a co-investigator on the clinical trial, ASCT1221 “A Randomized Phase II Study Comparing Two Different Conditioning Regiments Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myelomonocytic Leukemia (JMML).”

At UMSOM, Dr. Jeng is the Director of Medical Genomics and the laboratory director for the Translational Genomics Laboratory (CLIA #21D2027356, CAP #8017554) that is part of the new Center for Innovative Biomedical Resources (CIBR), a 30,000 square foot renovated space that allows for inter-core collaboration.  She is involved in implementation research projects including the recently concluded Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) (U01 HL105198-6, Shuldiner) and the current Personalized Diabetes Medicine Program (PDMP) (U01 HG007775, Pollin) for interdisciplinary investigations related to monogenic diabetes.  Dr. Jeng is also involved with medical genetics education, including teaching graduate students, medical students, residents, and fellows.

Clinical Molecular Genetics, Clinical Genetics, Genetics, Genomics, Pharmacogenetics, Pharmacogenomics, New Test Development, Test Validation, Translational Research, Implementation Science

• Cutting E, Banchero M, Beitelshees AL, Cimino JJ, Fiol GD, Gurses AP, Hoffman MA, Jeng LJ, Kawamoto K, Kelemen M, Pincus HA, Shuldiner AR, Williams MS, Pollin TI, Overby CL. User-centered design of multi-gene sequencing panel reports for clinicians. J Biomed Inform. 20Dr. Jeng is interested in the development of new molecular tests that can be offered in the clinical setting with a particular interest in clinical molecular genetics. She is especially interested in translational research, implementation science and providing molecular support for research protocols as appropriate.16 Jul 13;PubMed PMID: 27423699.
• Perry CG, Maloney KA, Beitelshees AL, Jeng L, Ambulos NP Jr, Shuldiner AR, Blitzer MG. Educational innovations in clinical pharmacogenomics. Clin Pharmacol Ther. 2016 Jun;99(6):582-4. PubMed PMID: 26875057.
• Kleinberger J, Maloney KA, Pollin TI, Jeng LJ. An openly available online tool for implementing the ACMG/AMP standards and guidelines for the interpretation of sequence variants. Genet Med. 2016 Mar 17;PubMed PMID: 26986878.
• Hegde M, Bale S, Bayrak-Toydemir P, Gibson J, Jeng LJ, Joseph L, Laser J, Lubin IM, Miller CE, Ross LF, Rothberg PG, Tanner AK, Vitazka P, Mao R. Reporting incidental findings in genomic scale clinical sequencing--a clinical laboratory perspective: a report of the Association for Molecular Pathology. J Mol Diagn. 2015 Mar;17(2):107-17. PubMed PMID: 25684271. 

Complete List of Published Work in My Bibliography:  http://bit.ly/2cLbh7z